KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Interest & Investment Income (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Interest & Investment Income for 18 consecutive years, with $25.5 million as the latest value for Q1 2026.

  • For Q1 2026, Interest & Investment Income rose 3.31% year-over-year to $25.5 million; the TTM value through Mar 2026 reached $98.6 million, down 6.47%, while the annual FY2025 figure was $97.8 million, 8.65% down from the prior year.
  • Interest & Investment Income hit $25.5 million in Q1 2026 for Ionis Pharmaceuticals, up from $24.7 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $28.9 million in Q4 2024 and bottomed at $2.0 million in Q1 2022.
  • Average Interest & Investment Income over 5 years is $20.2 million, with a median of $24.7 million recorded in 2025.
  • Year-over-year, Interest & Investment Income plummeted 57.08% in 2022 and then skyrocketed 834.62% in 2023.
  • Ionis Pharmaceuticals' Interest & Investment Income stood at $11.9 million in 2022, then skyrocketed by 116.14% to $25.7 million in 2023, then rose by 12.55% to $28.9 million in 2024, then dropped by 14.46% to $24.7 million in 2025, then rose by 3.05% to $25.5 million in 2026.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $25.5 million, $24.7 million, and $23.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.